Fecha de publicación: 24/12/2020 Fuente: WIPO "royal jelly" This invention discloses isolated protein fractions from Apis mellifera royal jelly (RJ) have proven potent efficacy in inhibiting leukemia cell growth and HIV-1 reverse transcriptase (RT) as well as releasing the cellular sialic acid (sialidase catalytic activity). Methods for RJ fractionation, the investigation against leukemia cell lines (NFS-60 and Jurkat cells), HIV-1 RT, and cellular SA are disclosed.